Hemera receives Orphan Drug Designation for REMaST® therapy

Jun 8, 2023 | News

REMaST® recognized as an orphan drug for acute spinal injuries The advanced cell therapy REMaST® developed by Hemera has been granted orphan drug designation by the European Commission for the treatment of acute spinal cord injuries. This important recognition...

Changed the structure of the Board of Directors

May 8, 2023 | News

Hemera’s Board of Directors: Updates in its structure For personal reasons, Aldo Cocchiglia is leaving the Board of Directors, effective May 3, 2023. Two years after the birth of Hemera, the shareholders express their gratitude to Ing. Cocchiglia for his...

New Composition of the Board of Directors

May 8, 2023 | News

Hemera Board of Directors: Updates to Its Composition For personal reasons, Aldo Cocchiglia will step down from the Board of Directors effective May 3, 2023. Two years after Hemera’s founding, the shareholders express their gratitude to Mr. Cocchiglia for his...

Our 2022, step by step

Dec 23, 2022 | News

Our 2022, step by step We close a very intense year that marked significant steps forward in the development of the first cellular therapy for the treatment of acute spinal cord injuries. Hemera has grown and been enriched with new skills, expanding the clinical board...